Current Gastroenterology Reports

, Volume 13, Issue 3, pp 271–278 | Cite as

Exploring the Differential Diagnosis of Joint Complaints in Pediatric Patients with Inflammatory Bowel Disease

  • Jennifer Dotson
  • Wallace Crandall
  • Sharon Bout-Tabaku
Article

Abstract

About one quarter of children with inflammatory bowel disease (IBD) experience an extraintestinal manifestation, with the most common being arthritis or arthralgia. Because of the frequency of these joint complaints and their effect on quality of life, it is important to consider all possible etiologies in order to promptly evaluate, diagnose, and possibly refer to other specialists. Pediatric gastroenterologist and IBD specialists are cognizant of the extraintestinal joint manifestations, but may be less familiar with rheumatic disease and the musculoskeletal examination. We explore the differential diagnosis of joint complaints in children, with a focus on IBD-related disease and rheumatic disease.

Keywords

Pediatric Inflammatory bowel disease Arthritis Arthralgia Rheumatology Differential diagnosis Evaluation Joint Extraintestinal manifestations IBD arthropathy Musculoskeletal pain Orthopedic 

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. 1.
    Dotson JL, Hyams JS, Markowitz J, et al. Extraintestinal manifestations of pediatric inflammatory bowel disease and their relation to disease type and severity. J Pediatr Gastroenterol Nutr. 2010;17(1):56–61.Google Scholar
  2. 2.
    Jose FA, Garnett EA, Vittinghoff E, et al. Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2009;15(1):63–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Hyams JS. Extraintestinal manifestations of inflammatory bowel disease in children. J Pediatr Gastroenterol Nutr. 1994;19(1):7–21.PubMedCrossRefGoogle Scholar
  4. 4.
    Oliva-Hemker M. More than a gut reaction: extraintestinal complications of IBD. Contemp Pediatr. 1999;16:45–64.Google Scholar
  5. 5.
    Passo MH, Fitzgerald JF, Brandt KD. Arthritis associated with inflammatory bowel disease in children. Relationship of joint disease to activity and severity of bowel lesion. Dig Dis Sci. 1986;31(5):492–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Palm O, Moum B, Jahnsen J, Gran JT. The prevalence and incidence of peripheral arthritis in patients with inflammatory bowel disease, a prospective population-based study (the IBSEN study). Rheumatol Oxf. 2001;40(11):1256–61.CrossRefGoogle Scholar
  7. 7.
    Grossman BJ, DeBenedetti CD. Extraintestinal manifestations of chronic inflammatory bowel disease in children. Proc Inst Med Chic. 1970;28(3):119.PubMedGoogle Scholar
  8. 8.
    Israel DM, Olson AD, Ilowite NT, Davidson M. Arthritis as the initial manifestation of inflammatory bowel disease in early infancy. J Pediatr Gastroenterol Nutr. 1989;9(1):123–5.PubMedCrossRefGoogle Scholar
  9. 9.
    Lindsley CB, Schaller JG. Arthritis associated with inflammatory bowel disease in children. J Pediatr. 1974;84(1):16–20.PubMedCrossRefGoogle Scholar
  10. 10.
    Al-Shamali MA, Kalaoui M, Patty I, et al. Ulcerative colitis in Kuwait: a review of 90 cases. Digestion. 2003;67(4):218–24.PubMedCrossRefGoogle Scholar
  11. 11.
    Palm O, Bernklev T, Moum B, Gran JT. Non-inflammatory joint pain in patients with inflammatory bowel disease is prevalent and has a significant impact on health related quality of life. J Rheumatol. 2005;32(9):1755–9.PubMedGoogle Scholar
  12. 12.
    •• Brakenhoff LK, van der Heijde DM, Hommes DW, et al. The joint-gut axis in inflammatory bowel diseases. J Crohns Colitis. 2010;4(3):257–68. This article serves as a review of various arthropathies associated with inflammatory bowel disease, including axial and peripheral arthropathies, evaluation techniques, pathophysiology, and treatment modalities.PubMedCrossRefGoogle Scholar
  13. 13.
    Lehman TJA. A clinician’s guide to rheumatic disease in children. New York: Oxford University Press, Inc; 2009. p. 417.Google Scholar
  14. 14.
    McInerny TK AH, Campbell DE, et al. American academy of pediatrics textbook of primary care. Elk Grove Village: American Academy of Pediatrics; 2009. p. 1625–36.Google Scholar
  15. 15.
    Perlman MH, Patzakis MJ, Kumar PJ, Holtom P. The incidence of joint involvement with adjacent osteomyelitis in pediatric patients. J Pediatr Orthop. 2000;20(1):40–3.PubMedCrossRefGoogle Scholar
  16. 16.
    Taccetti G, Trapani S, Ermini M, Falcini F. Reactive arthritis triggered by Yersinia enterocolitica: a review of 18 pediatric cases. Clin Exp Rheumatol. 1994;12(6):681–4.PubMedGoogle Scholar
  17. 17.
    Krumrey-Langkammerer M, Hafner R. Evaluation of the ILAR criteria for juvenile idiopathic arthritis. J Rheumatol. 2001;28(11):2544–7.PubMedGoogle Scholar
  18. 18.
    Jaakkola E, Herzberg I, Laiho K, et al. Finnish HLA studies confirm the increased risk conferred by HLA-B27 homozygosity in ankylosing spondylitis. Ann Rheum Dis. 2006;65(6):775–80.PubMedCrossRefGoogle Scholar
  19. 19.
    Salvarani C, Fries W. Clinical features and epidemiology of spondyloarthritides associated with inflammatory bowel disease. World J Gastroenterol. 2009;15(20):2449–55.PubMedCrossRefGoogle Scholar
  20. 20.
    De Vos M. Joint involvement associated with inflammatory bowel disease. Dig Dis. 2009;27(4):511–5.PubMedCrossRefGoogle Scholar
  21. 21.
    Beigel F, Schnitzler F, Paul Laubender R, et al. Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-alpha antibody-treated patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17(1):91–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Colombel JF, Loftus Jr EV, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126(1):19–31.PubMedCrossRefGoogle Scholar
  23. 23.
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Han PD, Cohen RD. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn’s disease. Drugs. 2004;64(16):1767–77.PubMedCrossRefGoogle Scholar
  25. 25.
    Kugathasan S, Levy MB, Saeian K, et al. Infliximab retreatment in adults and children with Crohn’s disease: risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol. 2002;97(6):1408–14.PubMedCrossRefGoogle Scholar
  26. 26.
    •• Goff I, Bateman B, Myers A, Foster H. Acceptability and practicality of musculoskeletal examination in acute general pediatric assessment. J Pediatr. 2010;156(4):657–62. This article is of particular importance because it discusses the use of pGALs in a clinical setting and highlights portions of the pGALS screening.PubMedCrossRefGoogle Scholar
  27. 27.
    Foster HE, Kay LJ, Friswell M, et al. Musculoskeletal screening examination (pGALS) for school-age children based on the adult GALS screen. Arthritis Rheum. 2006;55(5):709–16.PubMedCrossRefGoogle Scholar
  28. 28.
    Gniewek RA, Sandbulte C, Fox PC. Comparison of antinuclear antibody testing methods by ROC analysis with reference to disease diagnosis. Clin Chem. 1997;43(10):1987–9.PubMedGoogle Scholar
  29. 29.
    Gotthardt M, Bleeker-Rovers CP, Boerman OC, Oyen WJ. Imaging of inflammation by PET, conventional scintigraphy, and other imaging techniques. J Nucl Med. 2010;51(12):1937–49.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Jennifer Dotson
    • 1
  • Wallace Crandall
    • 1
  • Sharon Bout-Tabaku
    • 2
  1. 1.Division of Pediatric GastroenterologyNationwide Children’s HospitalColumbusUSA
  2. 2.Division of RheumatologyNationwide Children’s HospitalColumbusUSA

Personalised recommendations